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Evidence of systemic and pulmonary endothelial dysfunction in the 
dimethylarginine Dimethylaminohydrolase I (DDAH I+/-) heterozygous 
knockout mouse. 
M. Malaki, M. Nandi, M. Madhani, H. Gill, C. Smith, J. Leiper, P. Vallance 
Centre for Clinical Pharmacology and Therapeutics, BHF Laboratories, 
University College London, London, GB. 
 
Background: Asymmetric dimethylarginine (ADMA) is a naturally occurring 
endogenous inhibitor of all three isoforms of nitric oxide synthase. Increased 
levels of ADMA have been associated with conditions such as 
hypercholesterolaemia, diabetes and hypertension, where there is evidence of 
endothelial dysfunction. ADMA is metabolised by the enzyme, 
dimethylarginine dimethylaminohydrolase (DDAH). Two DDAH isoforms are 
present in mammals (DDAH I and II). Inhibition of DDAH leads to increased 
ADMA levels and endothelial dysfunction. Reduced expression of DDAH 
and/or elevated ADMA levels have been reported in human and animal 
models of pulmonary hypertension. 
 
Methods: We created a heterozygous knockout DDAH I+/- on a 
C57Black/SV129 background. Concentration of ADMA and DDAH expression 
were determined by high performance liquid chromatography and western 
blotting, respectively. Vascular function was studied in vitro using standard 
organ bath pharmacology, and in vivo by measuring systemic and right 
ventricular pressures. Structural differences in pulmonary vessels were 
assessed histologically. 
 
Results: The DDAH I +/- had reduced DDAH I protein expression in all 
tissues examined, and had increased circulating (0.69±0.02uM 
vs.0.87±0.06uM, p<0.05, n=12 per group) and tissue ADMA levels 
(2.87±0.24uM vs 3.68±0.31uM, p<0.05, n=12 per group) compared to their 
wild type littermates. Vascular studies revealed an impairment of endothelium 
dependent (ACh) relaxations both in the aorta and pulmonary arteries of 
DDAH+/- compared to wild types (aorta,p<0.05, 2- way ANOVA, n=5; 
pulmonary, p<0.05, 2-way ANOVA, n=7). In vivo there were no significant 
differences in systemic blood pressures, but the DDAH I +/- mice had higher 
right ventricular pressures (16.79±0.49 mm Hg vs 14.97±0.62 mm Hg, 
p<0.001, n=7). Examination of the pulmonary vasculature revealed increased 
medial smooth muscle area of resistance vessels in DDAH I +/- mice 
consistent with the raised RV pressures. 
 
Conclusions: These studies establish DDAH I as a key determinant of ADMA 
levels in vivo and demonstrate a causal relationship between ADMA and 
cardiovascular pathophysiology. 
 
